The pivotal cardiovascular trial for oral semaglutide is the SOUL trial published in the New England Journal of Medicine in 2025
Thankfully, pill-format varieties are also available, which may help patients who struggle with negative addiction-related associations to injections
The numbers As of July 31, 2025, the FDA had received a combined 1,150 adverse event reports related to compounded versions of semaglutide and tirzepatide
Medi-Weightloss, the leading physician-supervised weight loss brand, is proud to announce the opening of its newest clinic in Chesterfield, Missouri
Wegovy 7.2 mg The New, Higher-Strength Option The Wegovy 7.2mg pen is the latest and most advanced addition to the Wegovy range
Most research vendors offer significant per-vial discounts on multi-vial orders